Together we will beat cancer

Donate now
  • For Researchers

The Appraisal – Does a charity have a role in biotech and pharma innovation?

by Phil Prime | Podcast

17 August 2023

0 comments 0 comments

In this new podcast series, Executive Director of Research & Innovation at Cancer Research UK and CEO of Cancer Research Horizons, Dr Iain Foulkes brings you crisp insight and analysis from the sharp end of research leadership.


A recent report from Deloitte has shed new light on the staggering cost of developing new drugs – an expense that now exceeds $2 billion per therapy on average. It’s a cost only matched by the huge risk in undertaking the research and development needed to get a drug or intervention to market. So, is the ‘innovation economy’ of drug discovery sustainable? What can – perhaps should – be done about this? And does a charity like CRUK have a role here? Time to get some perspective on all this from Iain…

Some useful links:

Cancer Research Horizons is CRUK’s innovation engine built to complement it’s network of researchers. They take innovations from the lab bench to the bedside, translating them into effective treatments and diagnostics for cancer patients.

The report from Deloitte showing the cost of developing new drugs – an expense that now exceeds $2 billion per therapy on average.

FDA Commissioner Rob Califf says drug prices are too high.

Tell us what you think

Leave a Reply

Your email address will not be published. Required fields are marked *

Read our comment policy.

Tell us what you think

Leave a Reply

Your email address will not be published. Required fields are marked *

Read our comment policy.